Ariston Holding N.V. financials
Ariston Holding N.V.
Country: IT Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
815600CC86D25A205563 Financial statements
(EUR, as reported — unscaled; 109 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Other income | €40.2M | €47.5M |
| Employee benefits expense | €666.5M | €667.4M |
| Raw materials & consumables used | €1.24B | €1.10B |
| Depreciation & amortisation | €138.9M | €139.7M |
| Operating profit (EBIT) | €178.2M | €63.3M |
| Net finance income / (cost) | -€35.2M | -€45.0M |
| Finance costs | €42.2M | €48.8M |
| Profit before tax | €133.8M | €13.7M |
| Income tax expense | €1.2M | €11.4M |
| Profit for the year | €132.5M | €2.3M |
| — attributable to owners | €132.4M | €2.5M |
| — attributable to NCI | €100.0K | -€200.0K |
| Total comprehensive income | €114.6M | -€11.9M |
| Per share | ||
| Basic EPS | €0.36 | €0.01 |
| Diluted EPS | €0.36 | €0.01 |
| Free cash flow / share | €0.53 | €0.98 |
| Cash flow statement | ||
| Cash generated from operations | €376.8M | €257.3M |
| Net cash from operating activities | €303.3M | €306.5M |
| Income taxes paid | €33.8M | €51.2M |
| Net cash from investing activities | -€166.5M | -€134.6M |
| Purchase of PP&E (capex) | €107.5M | €82.1M |
| Purchase of intangibles | €38.1M | €33.7M |
| Net cash from financing activities | -€234.1M | -€264.3M |
| Dividends paid | €29.5M | €63.1M |
| Net change in cash | -€97.3M | -€92.4M |
| Balance sheet | ||
| Total assets | €3.58B | €3.57B |
| Non-current assets | €2.33B | €2.29B |
| Intangible assets & goodwill | €1.49B | €1.50B |
| Inventories | €511.0M | €470.4M |
| Trade & other receivables | €347.8M | €333.9M |
| Cash & equivalents | €246.5M | €350.8M |
| Total equity | €1.52B | €1.43B |
| — attributable to owners | €1.52B | €1.43B |
| Non-controlling interests | -€1.0M | -€700.0K |
| Non-current liabilities | €1.11B | €1.19B |
| Trade & other payables | €504.9M | €444.2M |
| Deferred tax liabilities | €181.8M | €208.7M |
| Derived metrics | ||
| Free cash flow | €195.8M | €224.4M |
| Operating margin | 6.6% | 2.4% |
| Net margin | 4.9% | 0.1% |
| Return on equity | 8.7% | 0.2% |
| Cash conversion ratio | 2.29× | 133.26× |
| Capex coverage | 2.82× | 3.73× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€10.1M | €119.0M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€4.0M | €23.6M |
| Adjustments For Income Tax Expense | €1.2M | €11.4M |
| Adjustments For Increase Decrease In Trade and Other Payables | €61.8M | -€43.4M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €238.4M | €345.2M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | -€69.3M | -€47.7M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €24.5M | €22.0M |
| Changes In Inventories of Finished Goods and Work In Progress | -€11.6M | €121.7M |
| Comprehensive Income Attributable To Noncontrolling Interests | €100.0K | -€200.0K |
| Comprehensive Income Attributable To Owners of Parent | €114.5M | -€11.7M |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €1.24B | €1.28B |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | €947.7M | €950.2M |
| Deferred Tax Assets | €126.0M | €122.1M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€9.5M | -€2.4M |
| Equity and Liabilities | €3.58B | €3.57B |
| Expense By Nature | €2.57B | €2.62B |
| Finance Income | €6.6M | €9.4M |
| Gain Recognised In Bargain Purchase Transaction | €41.1M | €0 |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | €400.0K | -€5.5M |
| Impairment Loss Recognised In Profit Or Loss | €12.2M | €5.1M |
| Increase Decrease In Cash and Cash Equivalents | -€106.8M | -€94.8M |
| Increase Decrease In Cash and Cash Equivalents Discontinued Operations | €0 | €0 |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €2.9M | €2.5M |
| Increase Decrease Through Transfers and Other Changes Equity | €2.9M | €6.8M |
| Interest Received Classified As Investing Activities | €4.4M | €6.8M |
| Investment Accounted For Using Equity Method | €12.9M | €5.1M |
| Issued Capital | €46.5M | €46.5M |
| Land and Buildings | €212.5M | €203.0M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €1.7M | €300.0K |
| Noncurrent Provisions For Employee Benefits | €78.4M | €85.0M |
| Other Adjustments To Reconcile Profit Loss | €12.2M | €5.1M |
| Other Comprehensive Income | -€17.9M | -€14.3M |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | €3.9M | -€2.8M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€24.7M | -€11.8M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €2.9M | €400.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€20.8M | -€14.6M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €2.9M | €400.0K |
| Other Current Assets | €86.7M | €62.8M |
| Other Current Financial Assets | €11.9M | €18.4M |
| Other Current Financial Liabilities | €30.5M | €46.8M |
| Other Current Liabilities | €275.0M | €241.9M |
| Other Expense By Nature | €26.5M | €68.8M |
| Other Inflows Outflows of Cash Classified As Financing Activities | €300.0K | €800.0K |
| Other Inflows Outflows of Cash Classified As Investing Activities | €1.5M | -€3.5M |
| Other Intangible Assets | €600.5M | €603.4M |
| Other Longterm Provisions | €82.2M | €69.6M |
| Other Noncurrent Assets | €8.3M | €7.0M |
| Other Noncurrent Financial Assets | €2.1M | €5.1M |
| Other Noncurrent Liabilities | €34.8M | €24.0M |
| Other Property Plant and Equipment | €217.5M | €187.1M |
| Other Shortterm Provisions | €50.0M | €62.8M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €1.5M | €4.7M |
| Proceeds From Government Grants Classified As Investing Activities | €4.5M | €0 |
| Proceeds From Issue of Ordinary Shares | €0 | €0 |
| Proceeds From Noncurrent Borrowings | €100.8M | €2.3M |
| Profit Loss From Continuing Operations | €132.5M | €2.3M |
| Property Plant and Equipment Including Rightofuse Assets | €689.9M | €648.5M |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | €8.3M | €4.9M |
| Purchase of Treasury Shares | €1.0M | €11.8M |
| Repayments of Noncurrent Borrowings | €195.8M | €103.5M |
| Revenue and Operating Income | €2.75B | €2.68B |
| Revenue From Contracts With Customers | €2.71B | €2.63B |
| Services Expense | €493.2M | €461.5M |
| Share Premium | €711.3M | €711.3M |
Methodology
Every line item above is a fact tagged in Ariston Holding N.V.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.